Neiloufar Family

[David Luke @drdluke]

...and the qualitative study of low dose LSD here https://t.co/eHwqe7kJKb #lsdtrip #psychedelic #psychedelics #psychology

[David Luke @drdluke]

The first of our publications from the our low dose LSD clinical trial https://t.co/ogQMfSn00n #lsdtrip #psychedelic #psychedelics #psychology

[Eleusis @EleusisLtd]

.@endpts news of our #Phase1 LSD study @ #subperceptual dose gives snapshot of Eleusis's clinical program moving forward. Plan for “not-so-psychedelic” serotonin 5-HT2A agonist #ELE02 our lead candidate in ophthalmology #RetinalDisease in preclinical stage
https://t.co/FJ1uzFQlzD

[Katrin Preller @KatrinPreller]

How does a #microdose of #LSD change brain connectivity? Take a look at our new paper with @Abershad and the de Wit lab at University of Chicago: https://t.co/W82sCYR8CK

[Endpoints News @endpts]

#Psychedelic research gains momentum, as early trial suggests micro-dosing #LSD is safe https://t.co/9Tf59bS4Ug

[Neiloufar Family @neiloufar]

@RCarhartHarris @ManojDoss It's the same study, so you're both right. The time perception task was part of this DB-RCT.

[Neiloufar Family @neiloufar]

@ManojDoss Could be interesting, but really hoping to see results coming from studies on populations with a relevant pathology.

[Neiloufar Family @neiloufar]

@willgiardino Re-tweeted it thanks!

[Neiloufar Family @neiloufar]

Happy to announce the publication of our phase 1 results of low dose LSD in older healthy adults. @EleusisLtd https://t.co/FGFRC009RO

[Neiloufar Family @neiloufar]

@ManojDoss Yea, certainly didn't find nootropic effects in this population, but looking forward to seeing how it works in a population with MCI or early AD.

[Eleusis @EleusisLtd]

Our #Phase1 clinical trial results published in journal #Psychopharmacology today: shows LSD is well-tolerated in healthy older adults, this allows us to look toward #Phase2 & research LSD's significant potential in treating #AlzheimersDisease
https://t.co/qis3InyHET

[Endpoints News @endpts]

Psychedelic research gains momentum, as early trial suggests micro-dosing LSD is safe https://t.co/9Tf59bS4Ug

[Eleusis @EleusisLtd]

#Psychedelics vs. cannabis insight @ATAI_life: "Unlike cannabis, psychedelics are a service, not a product." Agree, psychedelic psychotherapy is a service & must ensure safe/effective delivery; essential to secure #RegulatoryApproval & ecosystem scale-up https://t.co/iQu3zXvRhW

[Eleusis @EleusisLtd]

Congrats @COMPASSPathway for further advancing the clinical evaluation of #psilocybin and #psychedelicpsychotherapy
https://t.co/zla4eYXt4s

[Natalie Gukasyan, MD @N_Gukasyan]

Recruitment is open for a clinical trial of #psilocybin in people with #anorexia nervosa (esp. folks in #Baltimore/#DC area). #psychedelics #eatingdisorder #edrecovery @JHPsychedelics @JohnsHopkins_ED @NEDAstaff https://t.co/vRLbmTBUr4

[Manoj Doss not exist @ManojDoss]

A bunch of nerds/#psychedelic scientists, including Mark Geyer, went to a metal show. @AmonAmarthBand #ISRP2019 @Drug_Researcher @pshendricks @FredBarrettPhD @KatrinPreller @neiloufar

[Manoj Doss not exist @ManojDoss]

Psychedelics treat eye herpes. You learn something new everyday. #ISRP2019

[Neiloufar Family @neiloufar]

New from Eleusis: anti-inflammatory capacity of psychedelics in model of chronic asthma. Fibrosis 70% reduced after a few short treatments: psychedelics could potentially be used to treat symptoms of COPD, pulmonary hypertension, and asthma. https://t.co/sRAXDnOdJp